Emirates Drug Establishment (EDE) has approved Foundayo (orforglipron), an innovative oral treatment for chronic weight management, making the UAE the second country in the world to register the medication, developed by global pharmaceutical company Eli Lilly.
The move to approve this treatment is part of the establishment’s ongoing efforts to provide innovative, advanced and high-value therapies, particularly those that transform traditional treatment approaches by offering oral alternatives to injections and improving the patient experience, it said.
It also reflects EDE’s efforts to accelerate access to global pharmaceutical innovations for the UAE community, in line with the country’s directives to develop a leading pharmaceutical sector built on efficiency, innovation and sustainability.
Orforglipron is an oral glucagon-like peptide-1 (GLP-1) receptor agonist to be taken once daily without food or water intake restrictions to support weight reduction and the management of chronic obesity.
The treatment supports patients over the long term by helping regulate appetite and reduce excessive food intake, as part of a comprehensive programme focused on lifestyle modification and overall health improvement.
Dr Fatima Al Kaabi, Director-General of the Emirates Drug Establishment, said the UAE’s approval of orforglipron being the second country in the world is a significant step demonstrating the nation’s commitment to adopting the latest pharmaceutical innovations, particularly for people living with obesity.
She noted that orforglipron’s approval follows clinical trial results demonstrating the treatment’s effectiveness and patient response, stressing that tackling obesity is a priority for the Emirates Drug Establishment due to its association with an increased risk of more than 200 diseases and health complications, including type 2 diabetes and hypertension, in addition to at least 13 different types of cancer. – TradeArabia News Service
Send us your company’s news today and they could be featured on ABC’s Community News tommorow.
